Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Vincenza Bonanno"'
Autor:
Nicola Cascavilla, Felicina Li Gioi, Giuseppina Ricciuti, Maurizio Musso, Alessandra Crescimanno, Ferdinando Porretto, Gaetano De Santis, Emilio Iannitto, Annalisa Chiarenza, Ugo Consoli, Attilio Guarini, Maria Cristina Pirosa, Antonino Greco, Giuseppe Tarantini, Marilena Salerno, Saverio Mantuano, Carla Minoia, Donato Mannina, Francesco Di Raimondo, Alessandra Romano, Potito Rosario Scalzulli, Enzo Pavone, Renato Scalone, Anastasia Laura Caruso, Vincenza Bonanno
Publikováno v:
European journal of haematologyREFERENCES. 104(6)
Objective and methods In order to assess the efficacy of brentuximab vedotin (Bv) in combination with bendamustine (B) in multiple relapsed or refractory (RR) classic Hodgkin lymphoma (cHL), medical records of 47 patients treated with BvB in second r
Autor:
Vita Polizzi, Vincenza Bonanno, Maurizio Musso, Alessandra Crescimanno, Ferdinando Porretto, Renato Scalone
Publikováno v:
International Journal of Hematologic Oncology. 3:63-70
SUMMARY Autologous stem cell transplantation (ASCT), in chemosensitive relapsed patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL), is associated with superior event-free survival (EFS) compared with salvage chemotherapy alone
Autor:
Ilaria Scortechini, Lucia Mastrullo, Riccardo Boncompagni, Attilio Guarini, Carla Minoia, Maria Rosaria Villa, Angela Melpignano, Angela Rago, Fortunato Morabito, Maurizio Musso, Pier Luigi Zinzani, Vincenza Bonanno, Roberta Murru, Emanuele Angelucci, Giuseppe Tarantini, Carmine Selleri, Felicetto Ferrara, Luciano Levato, Stefano Molica, Giuseppe Cimino, Massimo Gentile, Maria Rosaria De Paolis, Stefania Ciolli, Angela Giannotta, Giuseppe Caparrotti, Nicola Di Renzo
BACKGROUND: The combination schedule of rituximab, fludarabine and cyclophosphamide is considered the standard therapy for fit and young untreated chronic lymphocytic leukemia (CLL) patients. However, although this therapy improves progression free s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64952d72ee0b2f6b61d764a36da9ded7
https://hdl.handle.net/11386/4654522
https://hdl.handle.net/11386/4654522
Autor:
Eugenio Piro, Salvatore Tafuto, Giuseppe Gargiulo, Lucio Catalano, Antonietta Falcone, Fiorella D'Auria, Michelino De Laurentiis, Nadia Caruso, Bruno Rotoli, Rita Rizzi, Fara Petruzziello, Pio Zeppa, Catello Califano, Fabrizio Pane, Francesco Di Raimondo, Immacolata Cozzolino, Maurizio Musso, Pellegrino Musto, Lucio Palombini, Vincenza Bonanno, Vincenzo Liso
Publikováno v:
Annals of Hematology
Annals of Hematology, Springer Verlag, 2009, 89 (5), pp.469-474. ⟨10.1007/s00277-009-0857-9⟩
Annals of Hematology, Springer Verlag, 2009, 89 (5), pp.469-474. ⟨10.1007/s00277-009-0857-9⟩
International audience; Systemic AL amyloidosis is associated with nearly 15% of cases of multiple myeloma, but data on the frequency and significance of amyloid deposits in the bone marrow of patients affected by multiple myeloma without clinical si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c60164be5ce146da5c2c36d93a1aca91
http://hdl.handle.net/11386/3879332
http://hdl.handle.net/11386/3879332
Autor:
Tania Perrone, Renato Scalone, Vincenza Bonanno, Alessandra Crescimanno, Vita Polizzi, Maurizio Musso, Carlo Bianchini, Ferdinando Porretto
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 17(2)
The objective of this study was to determine the efficacy of palonosetron combined with dexamethasone in prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving multiple-day chemotherapy and the efficacy
Autor:
Alessandra Crescimanno, Vita Polizzi, Maurizio Musso, Vincenza Bonanno, Ignazio Abbene, Ferdinando Porretto, Renato Scalone
Publikováno v:
Drugs and Cell Therapies in Hematology. 3:73
SUMMARY The heterogeneity of lymphomas results in a wide therapeutic options including both autologous and allogeneic hematopoietic stem cell transplantation (allo-HSCT). We reviewed the role of allo-HSCT in a high-risk group of aggressive non-Hodgki